($) USD (Default)
  • ($) AUD
  • (€) EUR
  • ($) CAD
  • ($) NZD
  • (£) GBP

B7-33 Pre-Mixed Peptide Pen

$28.57$79.30

B7-33 Pre-Mixed Peptide 2mg

Recent laboratory research has revealed the following benefits of B7-33:

  • Unprecedented anti-fibrotic power
  • Potential to reduce fibrinolysis in acute and chronic conditions
  • Promising potential to extend the life span of injured individuals
  • Novel treatment possibilities for heart failure
  • Preventing excessive scarring from cardiac injuries
  • Potential treatment for vascular disorders
  • Promotes joint health
  • Presence of relaxin-like anti-fibrotic properties in B7-33
  • Remarkable anti-inflammatory, antioxidant, and wound-healing properties in this peptide

495 in stock

First time customer gets 15% discount code = 1storder

B7-33 Pre-Mixed Peptide Pen America

B7-33 pre-mixed peptide is a remarkable single-chain peptide derived from H2-relaxin, a crucial water-soluble protein. Despite lacking cAMP activity and synthesis, B7-33 retains its sedative properties while triggering ERK1/2 phosphorylation, thus enhancing MMP2 synthesis and collagen degradation.

Within the relaxin protein family, notable members include relaxin, insulin-like peptide 3, H3-relaxin, and insulin-like peptide 5.

Insulin-related proteins have been extensively studied, revealing noteworthy musculoskeletal, cardiovascular, and reproductive effects.

Ground breaking research in animal studies demonstrates the numerous benefits of B7-33 pre-mixed peptide, including its potential to reduce heart damage and fibrinolysis in both acute and chronic diseases. Furthermore, it exhibits promising capabilities in treating vascular diseases and preventing cardiac injury-related scarring.


B7-33 Pre-Mixed Peptide Pen Benefits America

Reducing inflammation and wound healing qualities.

Relaxin receptors display diverse activities beyond cAMP activation. Alongside corticotropin-releasing factor (CRF), insulin-like peptides, GLP-1, orexin, and GLP-1 can also engage these receptors.

Extensive research and data analysis has proven that these activators exhibit anti-inflammatory, antioxidative, and wound-healing effects. As a result, Relaxin has emerged as the primary ligand for these receptors. Moreover, these agents demonstrate remarkable anti-fibrotic properties.

Pioneering investigations using animal models have unveiled Relaxin as a captivating vasodilator, blood vessel stimulant, and antihypertensive compound. Its multifaceted roles endow Relaxin with potent anti-fibrotic capabilities, driving exploration into its potential application for acute heart failure and other fibrotic disorders.

Reduction of Scar Tissue

Following cardiac damage, in clinical trials the B7-33 Peptide has exhibited its ability to reduce excessive scar tissue generation. Moreover, it holds promising potential in the treatment of long term vascular diseases and preeclampsia during pregnancy.

Decreased fibrosis

B7-33 exhibits potent anti-fibrotic properties, making it a compelling subject of scientific investigation for conditions like heart failure, lung inflammation, and renal disease. Recent research has shown promising results in using the B7-33 peptide to treat heart failure in animals, leading to prolonged survival post-injury and enhanced overall well-being.

There is also the option America to buy B7-33 Nasal Spray and B7-33 Peptide Vial.


References:

[1] https://pubmed.ncbi.nlm.nih.gov/ 32295457/

[2] https://pubmed.ncbi.nlm.nih.gov/28478069/

Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL

B7-33 HPLC Certificates


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our America Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.

Pen Instructions

All pre-mixed cartridges are mixed with 2ml bacteriostatic water, pens will release approximately 0.5ml per 60 dials on the pen (one full pen)

To achieve the number of micrograms (mcg) that 1 dial on the pen will release you will need to simply divide the amount of product:

2mg = 2000mcg

5mg = 5000mcg

by the full amount of pen dials (which will always be 240)

E.g., 5000mcg divided by 240 = 20.83, therefore 1 dial on the pen for all 5mg products will release approximately 20.83mcg.